Skip to main content

Table 1 Baseline characteristics of consented patients with migraine in the occupational health care register

From: Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care

  

Primary cohort subgroups

Failed prophylactic treatments at TT

Botox

G43, primary cohort

Prophylactic

Acute

No prescription

p

0

1

2

≥3

p

Follow-up time, median (min-max)

2.84 (0.09–6.00)

3.21 (0.11–6.00)

2.49 (0.09–6.00)

3.05 (0.09–6.00)

< 0.001

2.78 (0.09–6.00)

3.09 (0.11–6.00)

3.79 (0.13–6.00)

4.28 (0.36–6.00)

< 0.001

2.83 (0.09–6.00)

N

17,623

2199

6525

8899

< 0.001

15,424

1767

334

98

< 0.001

53

Female, %

78.9%

81.7%

80.5%

77.0%

< 0.001

78.5%

81.1%

84.4%

83.7%

0.002

83.0%

Age, mean

39 (15–77)

41 (15–70)

38 (15–77)

38 (15–75)

< 0.001

38 (15–77)

41 (15–70)

41 (17–68)

41 (21–61)

< 0.001

39 (20–68)

Prohpylactic prescription, n (%)

2199 (12.5)

2199 (100)

–

–

 

–

1767 (100)

334 (100)

98 (100)

 

53 (100)

Acute prescription only, n (%)

6525 (37)

–

6525 (100)

–

 

6525 (42.3)

–

–

–

 

–

No prescription, n (%)

8899 (50.5)

–

–

8899 (100)

 

8899 (57.7)

–

–

–

 

–

Prophylactic treatment lines

0, n (%)

15,424 (87.5)

–

6525 (100)

8899 (100)

 

15,424 (100)

–

–

–

 

–

1st, n (%)

1767 (10.0)

1767 (80.4)

–

–

 

–

1767 (100)

–

–

 

14 (26.4)

2nd, n (%)

334 (1.9)

334 (15.2)

–

–

 

–

–

334 (100)

–

 

18 (34.0)

3rd, n (%)

98 (0.6)

98 (4.5)

–

–

 

–

–

–

98 (100)

 

21 (39.6)

Botulinum toxin A, n (%)

53 (0.3)

53 (0.3)

–

–

 

–

–

–

–

 

53 (100)